

DRUG RISK MANAGEMENT IN JAPAN

-CONTENTS-

Chapter 1 Current status and future prospects of pharmaceutical approval review and safety policies in Japan

1. Introduction
2. Current status and issues related to development and approval review in Japan
 - 2.1 Current status and issues for clinical trials
 - 2.2 Current status and issues related to new drug review
3. Conditional approval system
 - 3.1 What is the conditional approval system?
 - 3.2 Current status and results of the conditional approval system
4. Current status and issues with post-marketing risk management
 - 4.1 New drug safety assurance and issues on it
 - 4.2 Safety monitoring from clinical trial stage

Chapter 2 Establishment and history of pharmaceutical regulations related to safety in Japan

1. History of drug-induced sufferings and the pharmaceutical regulatory system in Japan
2. SMON incident
 - 2.1 Summary of the SMON incident
 - 2.2 Lessons learned from the SMON incident and resulting improvements
3. Sorivudine incident
 - 3.1 Summary of the sorivudine incident
 - 3.2 Lessons learned from the sorivudine incident and resulting improvements
4. Conclusion

Chapter 3 Pharmaceutical risk management in Japan

1. Current status and issues
2. Future prospects

Chapter 4 Summary of the post-marketing surveillance system in Japan

1. Introduction
2. Adverse drug reactions and infections reporting system
 - 2.1 MAH reporting system
 - 2.2 Medical institution reporting system

- 2.3 WHO monitoring system
- 3. Early Post-marketing Phase Vigilance (EPPV) system
 - 3.1 Objective
 - 3.2 Target and method of EPPV
- 4. Periodic reporting system for infections
- 5. Reexamination system
 - 5.1 Reexamination period
 - 5.2 Process from application for approval until notification of Reexamination results
 - 5.3 Preparation of the Basic Plan for Post-marketing Studies
 - 5.4 Periodic safety reports and PSUR
 - 5.5 Reexamination results
- 6. Reevaluation system
 - 6.1 Reevaluation system
 - 6.2 Quality Reevaluations
- 7. Communication of results of Reexaminations/Reevaluations

Chapter 5 Post-marketing pharmacovigilance system

- 1. From GPMSP to GVP and GPSP
- 2. Establishment of the three Supervisors within MAHs
- 3. What is GVP?
- 4. What is GQP?
- 5. What is GPSP?
 - 5.1 GPMSP process and implementation of GPSP
- 6. What is GCP?

Chapter 6 Pharmacovigilance Inspections

- 1. GVP compliance evaluation and inspections (business inspections)
- 2. Conformity audits for Reexamination and Reevaluation application data (reliability assurance inspections/examinations)

Chapter 7 Relief Services System for Adverse Health Effects

- 1. Introduction
- 2. Summary of the Relief Services for Adverse Drug Reactions
 - 2.1 Scope of relief
 - 2.2 Process from application through decision on benefits
 - 2.3 Financial resources
 - 2.4 Statistics

3. Summary of the Relief Services for Infections derived from Biological Products

3.1 Scope of relief

3.2 Process from application through decision on benefits

3.3 Financial resources

3.4 Statistics

Chapter 8 General discussion on post-marketing pharmacovigilance

1. Collection of safety information by MAHs

1.1 Spontaneous information sources

1.2 Other information sources

1.3 Spontaneous ADR reports

2. Collection of safety information by MHLW and PMDA

2.1 Reports from medical institutions

2.2 Fixed-point observations of pharmacovigilance activities in medical institutions at early post-marketing stage

2.3 Pregnancy and Medicine Information Center

2.4 Establishment of a network of sentinel sites

3. Evaluation and analysis of safety information by MAHs

3.1 Assessment of individual cases

3.2 Assessment and analysis of collected information

3.3 Drug interactions

4. Evaluation and analysis of safety information by MHLW and PMDA

5. Safety assurance measures

5.1 Adverse drug reaction and infection reports to PMDA

5.2 Risk Minimization

5.3 Revision of Precautions

6. Post-marketing studies

6.1 Observational study and interventional study

6.2 Guidelines for post-marketing studies

6.3 Process of Drug Use Investigations

6.4 All-patient Investigations

6.5 Special Investigations

6.6 Post-marketing clinical trials

7. Provision and communication of information on proper use

7.1 Package inserts

7.2 Characteristics of provision and communication of information for proper use

7.3 Communication of information on proper use based on degree of importance

- 7.4 Japanese version of Drug Safety Update (DSU)
- 7.5 Explanation on “Precautions” of a new drug
- 7.6 Interview Form on prescription drug
- 7.7 Other information on proper use
- 7.8 Website of the Pharmaceuticals and Medical Devices Agency, Japan

Chapter 9 Comparison of Post-Marketing Surveillance system in Japan and overseas

- 1. Reporting of adverse drug reactions/infections
 - 1.1 Requirements for expedited reporting
 - 1.2 Requirements for periodic reports
- 2. Review of Indications, and Dosage and Administration
- 3. Guidelines for Contents of Prescribing Drug Information for healthcare professionals